For meningiomas with mutations in the Hedgehog (HH) pathway (SMO) or the NF2 pathway (FAK), targeted therapies such as vismodegib (an SMO inhibitor) and GSK2256098 (a FAK inhibitor) are being explored (NCT02523014). The gene discussed is NF2; the disease is meningioma.